Botox alternative set for launch in US

01 May 2009

Health regulators in the United States are set to give the green light to a new product that manufacturers claim could shake-up the non-invasive cosmetic surgery market.

With growing numbers of women and men turning to treatments such as Botox in a bid to combat the physical signs of ageing, it has been revealed that new wrinkle reduction product Dysport could be released to the public within the next few days.

Manufacturer Ipsen has teamed up with Medicis, which already owns popular non-invasive brands such as Restylane and Perlane, to promote the new treatment, with research carried out by the companies finding that it gives the same end-results as Botox but in a quicker time.

Dr Jeffrey Adelglass, a leading cosmetic physician, added: "The major benefits of Dysport to the cosmetic patient will be that there are fewer injections, and treatments hopefully will last a little longer."

News of the impending launch comes soon after the Food and Drug Administration (FDA) warned people against using treatments such as Botox without seeking professional advice first.